Scientific,Economic,Regulatory,and Ethical Challenges of Bringing Science-Based Pediatric Nutrition Products to the U.S. Market and Ensuring Their Availability for Patients

Abstract

Many nutrition products and related drugs are unavailable or not consistently available to clinicians despite a body of clinical data and experience supporting their use. Many of these can be related to drug shortages that have increased since 2009. In addition, there are potentially useful products that are not approved for a specific use or are no longer being manufactured. This review broadly examines the product availability gap from the perspectives of a clinician/former nutrition industry medical director and an economist. The process of pediatric nutrition product and related drug innovation, as well as its drivers and the steps involved in bringing a product to market, is first described. This is followed by an assessment of factors influencing product availability beyond the innovation process, including regulatory issues, manufacturing compliance, purchasing practices, and other factors related to drug and nutrition product pricing and reimbursement. Three pediatric case examples are reviewed and placed in the context of the prior review. Last, recent and future possible steps toward closing the product availability gap are discussed.

Keywords

pediatrics neonates life cycle public policy nutrition support practice reimbursement nutrition support practice

Get full access to this article

View all access options for this article.

References

Ventola

. The drug shortage crisis in the United States: causes, impact, and management strategies. Pharm Ther. 2011;36:740-742, 749-757.

Robbins

. Children are dying. Washingtonian. June 23, 2013.

“Shortages” search result. http://www.nutritioncare.org. Accessed June 25, 2014.

Holcombe

. Parenteral nutrition product shortages: impact on safety. JPEN J Parenter Enteral Nutr. 2012;36(2)(suppl):44S-47S.

Mirtallo

Holcombe

Kochevar

Guenter

. Parenteral nutrition product shortages: the A.S.P.E.N. strategy. Nutr Clin Pract. 2012;278:385-391.

Reich

. Essential drugs: economics and politics in international health. Health Policy. 1987;8:39-57.

Grossman

. On the concept of health capital and the demand for health. J Polit Econ. 1972;80(2):223-255.

Figlio

Guryan

Karbownik

Roth

. The Effects of Poor Neonatal Health on Children’s Cognitive Development. Evanston, IL: Institute for Policy Research, Northwestern University. Working Paper 13-08.

Case

Lubotsky

Paxson

. Economic status and health in childhood: the origins of the gradient. Am Econ Rev. 2002;92(5):1308-1334.

10.

Glewwe

Miguel

. The impact of child health and nutrition on education in less developed countries. In: Schultz

Strauss

, eds. Handbook of Development Economics. Vol 4. Amsterdam: North Holland; 2008:3561-3606.

11.

Hanson

Thoene

Wagner

Collier

Lecci

Anderson-Berry

. Parenteral nutrition additive shortages: the short-term long-term and potential epigenetic implications of premature and hospitalized infants. Nutrients. 2012;4:1977-1988.

12.

Kreider

Pepper

Gundersen

Jolliffe

. Identifying the effects of SNAP (Food Stamps) on child health outcomes when participation is endogenous and misreported. J Am Stat Assoc. 2012;107(499):958-975.

13.

Solow

. A contribution to the theory of economic growth. Q J Econ. 1956;70(1):65-94.

14.

Romer

. Increasing returns and long run growth. J Polit Econ. 1986;94(5):1002-1037.

15.

Howard

Jonkers-Schuitemab

Furnissa

. Managing the patient journey through enteral nutritional care. Clin Nutr. 2006;25:187-195.

16.

Currie

Moretti

. Mother’s education and the intergenerational transmission of human capital: evidence from college openings. Q J Econ. 2003;118(4):1495-1532.

17.

Duflo

. Child health and household resources in South Africa: evidence from the old age pension program. Am Econ Rev. 2000;90(2):393-398.

18.

Currie

Goodman

. Parental socioeconomic status, child health, and human capital. Int Encyclop Educ. 2010;3:253-259.

19.

Acosta

Matalon

. Nutrition management of patients with inherited disorders of aromatic amino acid metabolism. In: Acosta

, ed: Nutrition Management of Patients With Inherited Metabolic Disorders. Boston, MA: Jones & Bartlett; 2010:119-174.

20.

Fontaine

Garner

Bhan

. Oral rehydration therapy: the simple solution for saving lives. BMJ. 2007;33:4-14.

21.

Rice

. The peanut solution. New York Times Magazine. September 2, 2010.

22.

Vinnars

Wilmore

. History of parenteral nutrition. JPEN J Parenter Enteral Nutr. 2003;27:225-232.

23.

Winitz

Graff

Gallagher

Narkin

Seedman

. Evaluation of chemical diets for man-in-space. Nature. 1965;205:741.

24.

Space Food Systems Laboratory. NASA. February 21, 2013. http://www.nasa.gov/centers/johnson/slsd/about/divisions/hefd/facilities/space-food.html. Accessed June 24, 2014.

25.

Younoszai

. Gastrointestinal Function During Infancy in Infant Nutrition. 2nd ed. Philadelphia, PA: WB Saunders; 1974.

26.

Milgrom

Roberts

. The economics of modern manufacturing: technology, strategy, and organization. Am Econ Rev. 1990;80(3):511-528.

27.

Shah

. Effects of milk-derived bioactives: an overview. Brit J Nutr. 2000;84(suppl 1):S3-S10.

28.

Committee on the Evaluation of the Addition of Ingredients New to Infant Formula, Food and Nutrition Board, Institute of Medicine. Comparing infant formula with human milk and infant formula. In: Evaluating the Safety of New Ingredients. Washington, DC: National Academies Press; 2004:41-54.

29.

American Academy of Pediatrics Section on Breastfeeding: breastfeeding and the use of human milk. Pediatrics. 2012;29:e827-e841.

30.

Rulis

Levitt

. FDA’s food ingredient approval process: safety assurance based on scientific assessment. Regul Toxicol Pharm. 2009;53:20-31.

31.

Guidance for Industry: Demonstration of the quality factor requirements under 21 CFR 106.96(i) for “eligible” infant formulas. U.S. Food and Drug Administration. June 2014. http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/ucm400036.htm. Accessed June 24, 2014.

32.

Hathcock

. Dietary supplements: how they are used and regulated. J Nutr. 2001;131:114S-117S.

33.

DiMasi

Hansen

Grabowski

. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151-186.

34.

Gavura

. What does a new drug cost? Science-Based Medicine. April 4, 2011. http://www.sciencebasedmedicine.org/what-does-a-new-drug-cost/. Accessed June 24, 2014.

35.

Rawlins

. Cutting the cost of drug development. Nat Rev Drug Discov. 2004;3:360-364.

36.

Menon

. Pharmaceutical cost control in Canada: does it work? Health Affair. 2001;20:92-103.

37.

POST. Drug Pricing. Parliamentary Office of Science & Technology. October 2010. http://www.parliament.uk/documents/post/postpn_364_Drug_Pricing.pdf. Accessed July 7, 2014.

38.

Reinaud

. Generic price trends: a comparison across France, Germany Italy, Spain and the U.K. HIS healthcare and pharma blog. January 6, 2012. http://healthcare.blogs.ihs.com/2012/01/06/generic-drug-price-trends-france-germany-italy-spain-uk/. Accessed July 7, 2014.

39.

Lynas

. Provincial/territorial governments join forces to make further cuts to generic drug prices. Can Pharm J. 2013;146:68-70.

40.

Lanjouw

. Patents, Price Controls and Access to New Drugs: How Policy Affects Global Market Entry. Washington, DC: Center for Global Development; 2005. Working Paper 61.

41.

Frank

. Government commitment and regulation of prescription drugs. Health Affair. 2003;22:46-48.

42.

Ryan

Birch

. Charging for health care: evidence on the utilization of HS prescribed drugs. Soc Sci Med. 1991;33:681-687.

43.

Santerre

Neun

. Health Economics: Theories, Insights, and Industry Studies. 6th ed. Mason, OH: Cengage Learning, SouthWestern; 2013.

44.

Santerre

Vernon

. Private Consumer Demand for Pharmaceuticals in the U.S.: Own-Price, Cross-Price, and Income Elasticities. Storrs, CT: Center for Healthcare & Insurance Studies, University of Connecticut; 2004.

45.

Morton

FMS

. Entry decisions in the generic pharmaceutical industry. RAND J Econ. 1999;30(3):421-440.

46.

Gatesman

Smith

. The shortage of essential chemotherapy drugs in the United States. N Engl J Med. 2011;365:1653-1654.

47.

Werth

. Tale of two drugs. MITS Technol Rev. 2013;116:58-65.

48.

Rosenthal

. For drugs that save lives, a steep cost. New York Times. April 27, 2014.

49.

Wilensky

. Understanding the 340B program: a primer for health centers. National Association of Community Health Centers. November 2011. https://nachc.com/client/documents/5.11%20340%20Manual%20Primer%20for%20Health%20Centers2.pdf. Accessed June 25, 2014.

50.

Hayford

, for the Congressional Budget Office. Spending patterns for prescription drugs under Medicare Part D. Congressional Budget Office. December 2012. http://www.cbo.gov/sites/default/files/cbofiles/attachments/12-01-MedicarePartD.pdf. Accessed June 24, 2014.

51.

Mattingly

. Understanding drug pricing. US Pharm. 2012;36:40-45.

52.

Yurukoglu

. Medicare reimbursements and shortages of sterile injectable pharmaceuticals. National Bureau for Economic Research. April 2012. www.nber.org/papers/w17987. Accessed June 24, 2014.

53.

Roy

. How Margaret Hamburg’s FDA causes cancer drug shortages. Forbes. June 15, 2012. http://www.forbes.com/sites/theapothecary/2012/06/15/how-margaret-hamburgs-fda-causes-cancer-drug-shortages/. Accessed June 24, 2014.

54.

Nix

. How Medicare price controls have contributed to drug shortages. Heritage Foundation. December 21, 2011. http://www.heritage.org/research/reports/2011/12/how-medicare-price-controls-have-contributed-to-drug-shortages. Accessed June 24, 2014.

55.

U.S. Government Accountability Office Report to Congressional Addressees. Drug shortages: public health threat continues, despite efforts to help ensure product availability. U.S. Government Accountability Office. February 10, 2014. http://www.gao.gov/products/GAO-14-194. Accessed June 24, 2014.

56.

Health Care Supply Chain Association. A primer on group purchasing organizations. Health Care Supply Chain Association. 2011. www.SupplyChainAssociation.org. Accessed July 7, 2014.

57.

McKone-Sweet

Hamilton

Willis

. The ailing healthcare supply chain: a prescription for change. Supply Chain Manag. 2005;41:4-17.

58.

Schneller

. The value of group purchasing—2009: meeting the needs for strategic savings. Novation. 2009. https://www.novationco.com/media/industryinfo/value_of_gpo_2009.pdf. Accessed July 7, 2014.

59.

Nollet

Beaulieu

. Should an organisation join a purchasing group? Supply Chain Manag. 2005;10:11-17.

60.

Kohn

. GAO-12-399R: Group Purchasing Organizations. Washington, DC: U.S. Government Accountability Office; 2012.

61.

Zweig

Zellner

. Locked out of the hospital. Business Week. March 16, 1998.

62.

Walsh

. Senators investigate hospital purchasing. New York Times. August 13, 2009.

63.

DeLay

. Watch out for GPOs. Forbes. November 12, 2009. http://www.forbes.com/2009/11/12/gpo-medicare-hospitals-medical-health-opinions-contributors-daniel-delay.html. Accessed July 7, 2014.

64.

Sethi

. Group Purchasing Organizations: An Undisclosed Scandal in the US Healthcare Industry. New York, NY: Palgrave Macmillan; 2008.

65.

Cowie

. Group purchasing organizations and antitrust law: recent developments. Dechert. January 2011. http://www.dechert.com/files/Publication/df91e46d-c8f5-4f34-a294-00b40de5eb95/Presentation/PublicationAttachment/7fef9183-a1b2-459f-be06-10697655ad86/GPOs.pdf. Accessed July 7, 2014.

66.

Fox

Birt

James

Kokko

Salverson

Soflin

. ASHP guidelines on managing drug product shortages in hospitals and health systems. Am J Health Syst Pharm. 2009;66:1399-1406.

67.

Johnson

. Drug shortages: an increasing problem for patients and clinicians. S D Med. 2011;64:14-15.

68.

Kweder

Dill

. Drug shortages: the cycle of quantity and quality. Clin Pharmacol Ther. 2013;93:245-251.

69.

Singer

. Generics face longer wait for approval. New York Times. February 19, 2010.

70.

Comer

. New fees made FDA worse for generic drug approvals, says GPhA chairman. PharmExec. February 26, 2014. http://blog.pharmexec.com/2014/02/26/new-fees-made-fda-less-effective-on-generic-drug-approvals-says-gpha-chairman/. Accessed June 24, 2014.

71.

West

Dobson

. Corporate social responsibility in the pharmaceutical industry: a qualitative study. Can Pharm J. 2011;144:213-215.

72.

U.S. House of Representatives. Committee on Oversight and Government Reform. FDA’s Contribution to the Drug Shortage Crisis. Washington, DC: U.S. House of Representatives; June 2012.

73.

Woodcock

Wosinska

. Economic and technological drivers of generic sterile injectable drug shortages. Clin Pharmacol Ther. 2013;93:170-176.

74.

Darrow

Jerry Avorn

Kesselheim

. New FDA breakthrough-drug category— implications for patients. N Engl J Med. 2014;370:1252-1258.

75.

Kishimoto

Viswanathan

Ganguly

. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008;358:2457-2467.

76.

Outterson

. The Drug Quality and Security Act—mind the gaps. N Engl J Med. 2014;370:97-99.

77.

Fontanarosa

Rennie

DeAngelis

. Postmarketing surveillance—lack of vigilance, lack of trust. JAMA. 2004;292:2647-2650.

78.

Mitka

. Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety. JAMA. 2013;310:246-247.

79.

McGrath

. 10 Costly food recalls. How Stuff Works. March 12, 2009. http://money.howstuffworks.com/10-food-recalls.htm. Accessed June 24, 2014.

80.

Shields

. Food and drug law: the Infant Formula Act of 1980. Akron L Rev. 1982;15:752.

81.

Carpenter

. Groups, the media, agency waiting costs, and FDA drug approval. Am J Polit Sci. 2002;46(3):490-505.

82.

FDA approves Clinolipid for intravenous nutrition. FDA. October 3, 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370740.htm. Accessed July 3, 2014.

83.

Guidance for clinical investigators, sponsors, and IRBs: investigational new drug applications (INDs)—determining whether human research studies can be conducted without an IND. Food and Drug Administration. September 2013. http://www.fda.gov/downloads/Drugs/Guidance/UCM229175.pdf. Accessed June 24, 2014.

84.

Shenai

Kennedy

Chytil

Stahlman

. Clinical trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia. J Pediatr. 1987;111:269-277.

85.

Papagaroufalis

Cairis

Pantazatou

Meghreli

Xanthou

. A trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia. Pediatr Res. 1988;23:518A.

86.

Pearson

Bose

Snidow

. Trial of vitamin A supplementation in very low birth weight infants at risk for bronchopulmonary dysplasia. J Pediatr. 1992;121:420-427.

87.

Tyson

Wright

. Vitamin A supplementation for extremely low-birth-weight infants. N Engl J Med. 1999;340:1962-1968.

88.

Darlow

Graham

PJ.

Vitamin A supplementation to prevent mortality and short and longer term morbidity in very low birthweight infants. Cochrane Summaries. October 5, 2011. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000501.pub3/abstract. Accessed June 25, 2014.

89.

Londhe

Nolen

Das

. Vitamin A supplementation in extremely low-birth-weight infants: subgroup analysis in small-for-gestational-age infants. Am J Perinatol. 2013;30:771-780.

90.

Gadhia

Cutter

Abman

Kinsella

. Effects of early inhaled nitric oxide therapy and vitamin A supplementation on the risk of bronchopulmonary dysplasia in premature newborns with respiratory failure. J Pediatr. 2014;164:744-748.

91.

Ambalavanan

Tyson

Kennedy

. Vitamin A supplementation for extremely low birth weight infants: outcome at 18-22 months. Pediatrics. 2005;115:e249-e54.

92.

Chabra

Mayock

Zerzan

Bittner

Neufeld

Gleason

. Vitamin A status after prophylactic intramuscular vitamin A supplementation in extremely low birth weight infants. Nutr Clin Pract. 2013;28:381-386.

93.

Uberos

Miras Baldo

Jerez-Calero

Narbona-Lopez

. Effectiveness of vitamin A in the prevention of complications of prematurity [published online February 25, 2014]. Pediatr Neonatol.

94.

Kennedy

Stoll

Ehrenkranz

. Vitamin A to prevent bronchopulmonary dysplasia in very-low-birth-weight infants: has the dose been too low? Early Hum Dev. 1997;49:19-31.

95.

Reddy

. Current drug shortages in the United States. Int J Pharm Sci Nanotech. 2011;4:1433-1435.

96.

Meyer

Gortner

. Early postnatal additional high dose oral vitamin A supplementation versus placebo for 28 days for preventing bronchopulmonary dysplasia or death in extremely low birth weight infants. Neonatology. 2014;105:182-188.

97.

Stein

. Shortages of key drugs endanger patients. The Washington Post. May 1, 2011.

98.

Gura

Duggan

Collier

. Reversal of parenteral nutrition–associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics. 2006;118;197-201.

99.

Gura

Lee

Valim

. Safety and efficacy of a fish-oil based fat emulsion in the treatment of parenteral nutrition associated liver disease. Pediatrics. 2008;121;e678-e686.

100.

Ekema

Falchetti

Boroni

. Reversal of severe parenteral nutrition–associated liver disease in an infant with short bowel syndrome using parenteral fish oil (omega-3 fatty acids). J Pediatr Surg. 2008;43:1191-1195.

101.

Puder

Valim

Meisel

. Parenteral fish oil improves outcomes in patients with parenteral nutrition–associated liver injury. Ann Surg. 2009;250:395-402.

102.

Goulet

Antebi

Wolf

. A new intravenous fat emulsion containing soybean oil, medium-chain triglycerides, olive oil and fish oil: a single center, double-blind randomized study on efficacy and safety in pediatric patients receiving home parenteral nutrition. JPEN J Parenter Enteral Nutr. 2010;34:485-495.

103.

Diamond

Sterescu

Pencharz

Kim

Wales

. Changing the paradigm: Omegaven for the treatment of liver failure in pediatric short bowel syndrome. J Pediatr Gastrol Nutr. 2009;48:209-215.

104.

Reniers

Rajakumar

Ratko

Atkison

. Use of parenteral fish oil to reverse cholestasis induced by parenteral nutrition in infants with intestinal failure: single-centre case series. Can J Hosp Pharm. 2012;65:27-30.

105.

Sant’Anna

AMGA

Altamimi

Clause

R-F

. Implementation of a multidisciplinary team approach and fish oil emulsion administration in the management of infants with short bowel syndrome and parenteral nutrition-associated liver disease. Can J Gastroenterol. 2012;26:277-280.

106.

Calkins

Lowe

Shew

. Short-term intravenous fish oil and pediatric intestinal failure associated liver disease: 3-year follow-up on liver function and nutrition. Pediatr Surg. 2013;48:228-232.

107.

St-Jules

Watters

Iwamoto

. Use of fish oil–based lipid emulsions in infants with intestinal failure–associated liver disease: a case series. Infant Child Adolesc Nutr. 2014;6:6-12.

108.

Seida

Mager

Hartling

Vandermeer

Turner

. Parenteral ω-3 fatty acid lipid emulsions for children with intestinal failure and other conditions: a systematic review. JPEN J Parenter Enteral Nutr. 2013;37:44-55.

109.

U.S. Department of Health and Human Services. UNOS data. Transplants in the U.S. by recipient age. http://optn.transplant.hrsa.gov

110.

Mallah

Brown

Rossi

Block

. Orebterak fusgiuk–associated burr cell anemia. J Pediatr. 2010;156:324-326.

111.

Bonnot

. Omegaven: SMOF lipid basis of approvals. Paper presented at: FDA/ASPEN Public Workshop; October 29, 2013; Silver Spring, MD.

112.

Alfaleh

Anabrees

. Probiotics for prevention of necrotizing enterocolitis in preterm infants [review]. Cochrane Summaries. 2014. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005496.pub4/abstract. Accessed August 1, 2014.

113.

Bernardo

Aires

Carneiro

Sá

Rullo

Burns

. Effectiveness of probiotics in the prophylaxis of necrotizing enterocolitis in preterm neonates: a systematic review and meta-analysis. J Pediatr. 2013;89:18-24.

114.

Rosito

Slagle

. Probiotics for the prevention of necrotizing enterocolitis in neonates: an 8 hear retrospective cohort study. J Clin Pharm Ther. 2013;38:445-449.

115.

Braga

Pontes da Silva

Cabral de Lira

de Carvalho Lima

. Efficacy of Bifidobacterium breve and Lactobacillus casei oral supplementation on necrotizing enterocolitis in very-low-birth-weight preterm infants: a double-blind, randomized, controlled trial. Am J Clin Nutr. 2011;93:81-86.

116.

Lin

Hsu

Chen

. Oral probiotics prevent necrotizing enterocolitis in very low weight birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics. 2008;122:793-700.

117.

Neu

. Routine probiotics for premature infants: let’s be careful! J Pediatr. 2011;158:672-674.

118.

Reichert

. Trends in development and approval times for new therapeutics in the United States. Nat Rev. 2003;2:695-702.

119.

National Institutes of Health. Accelerating medicines partnership. May 5, 2014. http://www.nih.gov/science/amp/pdf/AMP-FactSheet.pdf. Accessed June 25, 2014.

120.

Nwaka

Ridley

. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat Rev. 2003;2:919-928.

121.

Rowe

Alexander

Kretser

. Principles for building public-private partnerships to benefit food safety, nutrition and health research. Nutr Rev. 2013;71:682-691.

122.

Montreal Statement on Research Integrity in Cross-Boundary Research Collaborations. Third World Conference on Research Integrity, Montreal. May 2013. http://www.wcri2013.org/Montreal_Statement_e.shtml. Accessed June 24, 2014.

123.

Nwaka

. Drug discovery and beyond: the rolf of public-private partnerships in improving access to new malaria medicines. Trans R Soc Trop Med Hyg. 2005;99:S20-S29.

124.

Widdus

. Public-private partnerships for health: their main targets, their diversity, and their future directions. Bull World Health Organ. 2001;79(8):713-720.

125.

Developing World Health Partnerships Directory. HIV/AIDS-R&D: pediatric formulations for ARVs. 2007. http://partnerships.ifpma.org/partnership/hiv-aids-r-d-pediatric-formulations-for-arvs

126.

Yasoo Health, Inc receives nearly $1 million to develop novel nutritional formulation. Yasoo Health. February 7, 2006. http://www.cff.org/UploadedFiles/aboutCFFoundation/NewsEvents/Yasoo%20Health%2002-07-06.pdf. Accessed June 25, 2014.

127.

Cystic Fibrosis Foundation. The importance of vitamins and minerals in CF. November 6, 2012. http://www.cff.org/LivingWithCF/StayingHealthy/Diet/Vitamins/. Accessed June 25, 2014.

128.

Vitamin Angels. Why Vitamins? http://www.vitaminangels.org. Accessed June 25, 2014.

129.

Partnership in Haiti. Malnutrition and lack of economic opportunity have plagued Haiti for many years. http://partnershipinhaiti.org. Accessed June 25, 2014.

130.

DeCamp

Joffe

Fernandez

Faden

Unguru

, on behalf of the Working Group on Chemotherapy Drug Shortages in Pediatric Oncology. Chemotherapy drug shortages in pediatric oncology: a consensus statement. Pediatrics. 2014;133:e716-e724.

131.

Hoffmann

Fraser

Palumbo

Ravel

Rowthorn

Schwartz

. Probiotics: finding the right regulatory balance. Science. 2013;342:314-315.

132.

Schweitzer

. How the US Food and Drug Administration can solve the prescription drug shortage problem. Am J Public Health. 2013;103(5):e10-e14.